Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pf-04620110 SCHEMBL1425038 | 1.00 | DGAT1 (1.00) | DGAT1 | |
| Pf-04620110 SCHEMBL1424362 | 1.00 | DGAT1 (1.00) | DGAT1 | |
| SCHEMBL16969183 | 0.93 | DGAT1 (0.86) | DGAT1 | |
| SCHEMBL1425086 | 0.92 | DGAT1 (1.00) | DGAT1 | |
| SCHEMBL1425091 | 0.92 | DGAT1 (1.00) | DGAT1 | |
| SCHEMBL3287325 | 0.91 | DGAT1 (0.83) | DGAT1 | |
| SCHEMBL15638520 | 0.90 | DGAT1 (0.82) | DGAT1 | |
| SCHEMBL13223427 | 0.89 | DGAT1 (1.00) | DGAT1 | |
| SCHEMBL3393024 | 0.89 | DGAT1 (1.00) | DGAT1 | |
| SCHEMBL3393771 | 0.89 | DGAT1 (0.84) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120154718-A | Functional hydrogel loaded with diacylglycerol acyltransferase inhibitor as well as preparation method and application thereof | 中国科学院苏州纳米技术与纳米仿生研究所 | 2025-06-17 | — | — | CN | claimed |
| WO-2025078630-A1 | DIACYLGLYCEROL-ACYLTRANSFERASE 1 INHIBITOR FOR USE IN A METHOD OF TREATING CANCER IN A HUMAN FEMALE PATIENT | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2025-04-17 | — | — | WO | claimed |
| EP-2185567-B1 | SUBSTITUTED BICYCLOLACTAM COMPOUNDS | PFIZER PROD INC (US) | 2011-03-23 | — | — | EP | claimed |
| JP-4629808-B2 | — | — | 2011-02-09 | — | — | JP | claimed |
| JP-2010535190-A | — | — | 2010-11-18 | — | — | JP | claimed |
| EP-2185567-A2 | SUBSTITUTED BICYCLOLACTAM COMPOUNDS | Pfizer Products Inc. (US) | 2010-05-19 | — | — | EP | claimed |
| US-7718645-B2 | Substituted bicyclolactam compounds | PFIZER INC. (US) | 2010-05-18 | — | — | US | claimed |
| US-20090137551-A1 | Substituted Bicyclolactam Compounds | PFIZER INC | 2009-05-28 | — | — | US | claimed |
| WO-2009016462-A2 | SUBSTITUTED BICYCLOLACTAM COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2009-02-05 | — | — | WO | claimed |
| US-20090036425-A1 | SUBSTITUTED BICYCLOLACTAM COMPOUNDS | PFIZER INC | 2009-02-05 | — | — | US | claimed |
| EP-3765012-B1 | DGAT1 INHIBITORS FOR USE IN TREATING CONSTIPATION | SERLEVA INC (US) | 2026-03-04 | — | — | EP | disclosed |
| US-20260000651-A1 | COMPOSITIONS AND METHODS FOR TREATING SEVERE CONSTIPATION | SERLEVA INC (US) | 2026-01-01 | — | — | US | disclosed |
| CN-120815181-A | Application of DGAT1 specific oral inhibitor in neurodegenerative diseases | 重庆医科大学 | 2025-10-21 | — | — | CN | disclosed |
| WO-2025201979-A1 | A METHOD FOR DEFATTENING A STEATOTIC LIVER EX VIVO BY PERFUSION USING A PI4KB INHIBITOR | ETH ZURICH (CH) | 2025-10-02 | — | — | WO | disclosed |
| EP-4623912-A1 | A METHOD FOR DEFATTENING A STEATOTIC LIVER EX VIVO | ETH Zurich (CH) | 2025-10-01 | — | — | EP | disclosed |
| US-20090137551-A1 | Substituted Bicyclolactam Compounds | PFIZER INC | 2009-05-28 | — | — | US | disclosed |
| WO-2009016462-A2 | SUBSTITUTED BICYCLOLACTAM COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| US-20090036425-A1 | SUBSTITUTED BICYCLOLACTAM COMPOUNDS | PFIZER INC | 2009-02-05 | — | — | US | disclosed |
| US-20090036425-A1 | SUBSTITUTED BICYCLOLACTAM COMPOUNDS | PFIZER INC | 2009-02-05 | — | — | US | disclosed |
| US-20090036425-A1 | SUBSTITUTED BICYCLOLACTAM COMPOUNDS | PFIZER INC | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260000651-A1 | COMPOSITIONS AND METHODS FOR TREATING SEVERE CONSTIPATION | DGAT1, DGAT2, SOAT1 | DGAT1 1/4885 |
| US-20090137551-A1 | Substituted Bicyclolactam Compounds | CHRM2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CXCR2 | DGAT1 4238/4885 |
| US-20090036425-A1 | SUBSTITUTED BICYCLOLACTAM COMPOUNDS | CHRM2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CXCR2 | DGAT1 4238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.